<DOC>
	<DOCNO>NCT02140450</DOCNO>
	<brief_summary>To assess effect prophylactic antiglaucoma agent prevention acute intraocular pressure rise intravitreal injection .</brief_summary>
	<brief_title>Effect Antiglaucoma Agents Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection</brief_title>
	<detailed_description>Acute intraocular pressure elevation intravitreal injection bevacizumab proven.Acute intraocular pressure elevation probably volume relate long term intraocular pressure elevation relate pharmacologic feature medication result anatomic change angle anterior chamber.Numerous study find intraocular pressure elevation right injection quick normalization within maximally 30 minutes.This intraocular pressure elevation last 30 minute , result irreversible visual loss especially patient critical remain nerve fiber optic nerve head , occur glaucomatous patient . Is way prevent even shorten time intraocular pressure elevation ? We try study find suitable response question , use several anti-glaucoma agent ( Timolol , Brimonidine , Acetazolamide , Mannitol versus placebo ) prophylaxis prevent acute intraocular pressure elevation right intravitreal bevacizumab injection .</detailed_description>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<mesh_term>Acetazolamide</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>patient candidate receive intravitreal bevacizumab patient advance glaucoma patient receive antiglaucoma agent past patient corneal scar affect IOP measurement</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>intraocular pressure , intravitreal injection , short term</keyword>
</DOC>